BISOPROLOL FUMARATE | A075474 | TP ANDA HOLDINGS LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consultant Services, Inc. FDA-2007-P-0177 · 7 docket documents Lachman Consultant Services, Inc. filed this citizen petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Bisoprolol Fumarate and Hydrochlorothiazide Tablets in strengths of 5 mg/12.5 mg, 10 mg/12.5 mg, and 20 mg/12.5 mg suitable for submissi | Other | 2008-05-06 | Partially Denied | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1955
per ea
Lowest NADAC/Unit
$0.1333
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 52817027110BISOPROLOL FUMARATE 10 MG TAB | $0.1955 | EA | Generic | — | 2026-06-17 |
| 52817027130BISOPROLOL FUMARATE 10 MG TAB | $0.1955 | EA | Generic | — | 2026-06-17 |
| 52817027010BISOPROLOL FUMARATE 5 MG TAB | $0.1333 | EA | Generic | — | 2026-06-17 |
| 52817027030BISOPROLOL FUMARATE 5 MG TAB | $0.1333 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.